Advertisement

Surgery Today

, Volume 44, Issue 5, pp 797–803 | Cite as

Colorectal cancer and hypercoagulability

  • Kazushige Kawai
  • Toshiaki WatanabeEmail author
Review Article

Abstract

Since the first report of the spontaneous appearance of venous thrombophlebitis as a sign of visceral cancer by Trousseau in 1865, many other studies have documented the existence of cancer-associated coagulation disorders. In this review, we describe the hypercoagulable state associated with colorectal cancer, from three perspectives: first, the incidence, risk factors and prevention of clinically symptomatic thromboembolic conditions associated with cancer, such as venous thromboembolism and arterial thrombosis; second, the association between hypercoagulable conditions, such as thrombocytosis, hyperfibrinogenemia, or d-dimer elevation, and the clinical progression and poor prognosis of cancer patients; third, the experimental approach to elucidate the role of various coagulation-related factors in the process of cancer progression, focusing specifically on the role of platelets and tissue factors.

Keywords

Hypercoagulability Colorectal cancer Platelets Fibrinogen d-dimer 

References

  1. 1.
    Varki A. Trousseau’s syndrome: multiple definitions and multiple mechanisms. Blood. 2007;110:1723–9.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Piccioli A, Lensing AW, Prins MH, et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost. 2004;2:884–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Aminian A, Karimian F, Mirsharifi R, et al. Significance of platelet count in esophageal carcinomas. Saudi J Gastroenterol. 2011;17:134–7.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Wang L, Huang X, Chen Y, Jin X, Li Q, Yi TN. Prognostic value of TP/PD-ECGF and thrombocytosis in gastric carcinoma. Eur J Surg Oncol. 2012;38:568–73.PubMedCrossRefGoogle Scholar
  5. 5.
    Komurcuoglu B, Ulusoy S, Gayaf M, Guler A, Ozden E. Prognostic value of plasma d-dimer levels in lung carcinoma. Tumori. 2011;97:743–8.PubMedGoogle Scholar
  6. 6.
    Yamashita H, Kitayama J, Kanno N, Yatomi Y, Nagawa H. Hyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer. BMC Cancer. 2006;6:147.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Tsihlias J, Grossman HB. The utility of fibrin/fibrinogen degradation products in superficial bladder cancer. Urol Clin North Am. 2000;27:39–46.PubMedCrossRefGoogle Scholar
  8. 8.
    Tas F, Kilic L, Bilgin E, et al. Clinical and prognostic significance of coagulation assays in advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2013;23:276–81.PubMedCrossRefGoogle Scholar
  9. 9.
    Schellerer VS, Mueller-Bergh L, Merkel S, et al. The clinical value of von Willebrand factor in colorectal carcinomas. Am J Transl Res. 2011;3:445–53.PubMedCentralPubMedGoogle Scholar
  10. 10.
    Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105:178–85.PubMedCrossRefGoogle Scholar
  11. 11.
    Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med. 2004;164:963–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Monreal M, Lensing AW, Prins MH, et al. Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost. 2004;2:876–81.PubMedCrossRefGoogle Scholar
  13. 13.
    Davenport DL, Vargas HD, Kasten MW, Xenos ES. Timing and perioperative risk factors for in-hospital and post-discharge venous thromboembolism after colorectal cancer resection. Clin Appl Thromb Hemost. 2012;18:569–75.PubMedCrossRefGoogle Scholar
  14. 14.
    Alcalay A, Wun T, Khatri V, et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol. 2006;24:1112–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e227S–77S.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11:56–70.PubMedCrossRefGoogle Scholar
  17. 17.
    Ay C, Pabinger I. Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients. Thromb Res. 2012;129(Suppl 1):S6–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Schutz FA, Je Y, Azzi GR, Nguyen PL, Choueiri TK. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol. 2011;22:1404–12.PubMedCrossRefGoogle Scholar
  20. 20.
    Kandemir EG, Mayadagli A, Karagoz B, Bilgi O, Turken O, Yaylaci M. Prognostic significance of thrombocytosis in node-negative colon cancer. J Int Med Res. 2005;33:228–35.PubMedCrossRefGoogle Scholar
  21. 21.
    Qiu MZ, Yuan ZY, Luo HY, et al. Impact of pretreatment hematologic profile on survival of colorectal cancer patients. Tumour Biol. 2010;31:255–60.PubMedCrossRefGoogle Scholar
  22. 22.
    Sasaki K, Kawai K, Tsuno NH, Sunami E, Kitayama J. Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer. World J Surg. 2012;36:192–200.PubMedCrossRefGoogle Scholar
  23. 23.
    Oya M, Akiyama Y, Okuyama T, Ishikawa H. High preoperative plasma d-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol. 2001;31:388–94.PubMedCrossRefGoogle Scholar
  24. 24.
    Stender MT, Larsen TB, Sorensen HT, Thorlacius-Ussing O. Preoperative plasma d-dimer predicts 1-year survival in colorectal cancer patients with absence of venous thromboembolism (VTE): a prospective clinical cohort study. J Thromb Haemost. 2012;10:2027–31.PubMedCrossRefGoogle Scholar
  25. 25.
    Yamashita H, Kitayama J, Taguri M, Nagawa H. Effect of preoperative hyperfibrinogenemia on recurrence of colorectal cancer without a systemic inflammatory response. World J Surg. 2009;33:1298–305.PubMedCrossRefGoogle Scholar
  26. 26.
    Tang L, Liu K, Wang J, Wang C, Zhao P, Liu J. High preoperative plasma fibrinogen levels are associated with distant metastases and impaired prognosis after curative resection in patients with colorectal cancer. J Surg Oncol. 2010;102:428–32.PubMedCrossRefGoogle Scholar
  27. 27.
    Wang WS, Lin JK, Lin TC, et al. Plasma von Willebrand factor level as a prognostic indicator of patients with metastatic colorectal carcinoma. World J Gastroenterol. 2005;11:2166–70.PubMedGoogle Scholar
  28. 28.
    Gadducci A, Marrai R, Baicchi U, Gagetti O, Facchini V, Genazzani AR. Prothrombin fragment F1 + 2 and thrombin-antithrombin III complex (TAT) plasma levels in patients with gynecological cancer. Gynecol Oncol. 1996;61:215–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Kwon HC, Oh SY, Lee S, et al. Plasma levels of prothrombin fragment F1 + 2, d-dimer and prothrombin time correlate with clinical stage and lymph node metastasis in operable gastric cancer patients. Jpn J Clin Oncol. 2008;38:2–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Tomimaru Y, Yano M, Takachi K, et al. Correlation between pretherapeutic d-dimer levels and response to neoadjuvant chemotherapy in patients with advanced esophageal cancer. Dis Esophagus. 2008;21:281–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Holgersson G, Sandelin M, Hoye E, et al. Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer. Med Oncol. 2012;29:3176–82.PubMedCrossRefGoogle Scholar
  32. 32.
    Kawai K, Kitayama J, Tsuno NH, Sunami E, Nagawa H. Hyperfibrinogenemia after preoperative chemoradiotherapy predicts poor response and poor prognosis in rectal cancer. Int J Colorectal Dis. 2011;26:45–51.PubMedCrossRefGoogle Scholar
  33. 33.
    Kawai K, Kitayama J, Tsuno NH, Sunami E, Watanabe T. Thrombocytosis before pre-operative chemoradiotherapy predicts poor response and shorter local recurrence-free survival in rectal cancer. Int J Colorectal Dis. 2012Google Scholar
  34. 34.
    Vossen CY, Hoffmeister M, Chang-Claude JC, Rosendaal FR, Brenner H. Clotting factor gene polymorphisms and colorectal cancer risk. J Clin Oncol. 2011;29:1722–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999;59:1295–300.PubMedGoogle Scholar
  36. 36.
    Gasic GJ. Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev. 1984;3:99–114.PubMedCrossRefGoogle Scholar
  37. 37.
    Gasic GJ, Gasic TB, Galanti N, Johnson T, Murphy S. Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease. Int J Cancer. 1973;11:704–18.PubMedCrossRefGoogle Scholar
  38. 38.
    Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost. 2011;105(Suppl 1):S13–33.PubMedCrossRefGoogle Scholar
  39. 39.
    Shida D, Kitayama J, Yamaguchi H, et al. Sphingosine 1-phosphate transactivates c-Met as well as epidermal growth factor receptor (EGFR) in human gastric cancer cells. FEBS Lett. 2004;577:333–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Yamashita H, Kitayama J, Shida D, et al. Sphingosine 1-phosphate receptor expression profile in human gastric cancer cells: differential regulation on the migration and proliferation. J Surg Res. 2006;130:80–7.PubMedCrossRefGoogle Scholar
  41. 41.
    Shida D, Kitayama J, Yamaguchi H, et al. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res. 2003;63:1706–11.PubMedGoogle Scholar
  42. 42.
    Mori K, Kitayama J, Shida D, Yamashita H, Watanabe T, Nagawa H. Lysophosphatidic acid-induced effects in human colon carcinoma DLD1 cells are partially dependent on transactivation of epidermal growth factor receptor. J Surg Res. 2006;132:56–61.PubMedCrossRefGoogle Scholar
  43. 43.
    Helley D, Banu E, Bouziane A, et al. Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Eur Urol. 2009;56:479–84.PubMedCrossRefGoogle Scholar
  44. 44.
    Dashevsky O, Varon D, Brill A. Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. Int J Cancer. 2009;124:1773–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Seto S, Onodera H, Kaido T, et al. Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer. 2000;88:295–301.PubMedCrossRefGoogle Scholar
  46. 46.
    Rao B, Gao Y, Huang J, et al. Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis. Int J Colorectal Dis. 2011;26:593–601.PubMedCrossRefGoogle Scholar
  47. 47.
    Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005;105:1734–41.PubMedCrossRefGoogle Scholar
  48. 48.
    Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007;13:2870–5.PubMedCrossRefGoogle Scholar
  49. 49.
    Verheul HM, Hoekman K, Lupu F, et al. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res. 2000;6:166–71.PubMedGoogle Scholar
  50. 50.
    Wojtukiewicz MZ, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in malignancy. Neoplasia. 2001;3:371–84.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Klepfish A, Greco MA, Karpatkin S. Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix. Int J Cancer. 1993;53:978–82.PubMedCrossRefGoogle Scholar
  52. 52.
    Chang LH, Chen CH, Huang DY, Pai HC, Pan SL, Teng CM. Thrombin induces expression of twist and cell motility via the hypoxia-inducible factor-1alpha translational pathway in colorectal cancer cells. J Cell Physiol. 2011;226:1060–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Tang JQ, Fan Q, Wu WH, et al. Extrahepatic synthesis of coagulation factor VII by colorectal cancer cells promotes tumor invasion and metastasis. Chin Med J. 2010;123:3559–65.PubMedGoogle Scholar
  54. 54.
    Choe KS, Correa D, Jani AB, Liauw SL. The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy. Cancer. 2010;116:1820–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Noble S. Low-molecular-weight heparin and survival in lung cancer. Thromb Res. 2012;129(Suppl 1):S114–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Maurer LH, Herndon JE 2nd, Hollis DR, et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol. 1997;15:3378–87.PubMedGoogle Scholar
  57. 57.
    Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367:1596–606.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  1. 1.Department of Surgical Oncology, Faculty of MedicineThe University of TokyoTokyoJapan

Personalised recommendations